
## David M Knipe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7925346/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1315-1320.	7.1	536
2	Chromatin control of herpes simplex virus lytic and latent infection. Nature Reviews Microbiology, 2008, 6, 211-221.	28.6	365
3	Vaginal Submucosal Dendritic Cells, but Not Langerhans Cells, Induce Protective Th1 Responses to Herpes Simplex Virus-2. Journal of Experimental Medicine, 2003, 197, 153-162.	8.5	364
4	Nuclear IFI16 induction of IRF-3 signaling during herpesviral infection and degradation of IFI16 by the viral ICP0 protein. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3008-17.	7.1	363
5	The intranuclear location of a herpes simplex virus DNA-binding protein is determined by the status of viral DNA replication. Cell, 1984, 36, 857-868.	28.9	356
6	Formation of DNA replication structures in herpes virus-infected cells requires a viral DNA binding protein. Cell, 1988, 55, 857-868.	28.9	291
7	Herpesviral latency-associated transcript gene promotes assembly of heterochromatin on viral lytic-gene promoters in latent infection. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16055-16059.	7.1	226
8	cGAS-mediated stabilization of IFI16 promotes innate signaling during herpes simplex virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1773-81.	7.1	220
9	Proteomics of Herpes Simplex Virus Replication Compartments: Association of Cellular DNA Replication, Repair, Recombination, and Chromatin Remodeling Proteinswith ICP8. Journal of Virology, 2004, 78, 5856-5866.	3.4	208
10	A Promiscuous Lipid-Binding Protein Diversifies the Subcellular Sites of Toll-like Receptor Signal Transduction. Cell, 2014, 156, 705-716.	28.9	192
11	Transcription of the Herpes Simplex Virus Latency-Associated Transcript Promotes the Formation of Facultative Heterochromatin on Lytic Promoters. Journal of Virology, 2009, 83, 8182-8190.	3.4	189
12	Herpes Simplex Virus 1 Has Multiple Mechanisms for Blocking Virus-Induced Interferon Production. Journal of Virology, 2004, 78, 8411-8420.	3.4	173
13	<scp>HSV</scp> â€1 <scp>ICP</scp> 27 targets the <scp>TBK</scp> 1â€activated STING signalsome to inhibit virusâ€induced type I <scp>IFN</scp> Âexpression. EMBO Journal, 2016, 35, 1385-1399.	7.8	173
14	Herpes Simplex Virus ICP0 Promotes both Histone Removal and Acetylation on Viral DNA during Lytic Infection. Journal of Virology, 2008, 82, 12030-12038.	3.4	171
15	Replication-defective viruses as vaccines and vaccine vectors. Virology, 2006, 344, 230-239.	2.4	160
16	Nuclear interferon-inducible protein 16 promotes silencing of herpesviral and transfected DNA. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4492-501.	7.1	146
17	Numerous Conserved and Divergent MicroRNAs Expressed by Herpes Simplex Viruses 1 and 2. Journal of Virology, 2010, 84, 4659-4672.	3.4	145
18	Herpes simplex Virus a Protein ICP27 Can Inhibit or Augment Viral Gene Transactivation. Virology, 1989, 170, 496-504.	2.4	138

#	Article	IF	CITATIONS
19	Snapshots: Chromatin control of viral infection. Virology, 2013, 435, 141-156.	2.4	133
20	Herpes Simplex Virus 1 U L 31 and U L 34 Gene Products Promote the Late Maturation of Viral Replication Compartments to the Nuclear Periphery. Journal of Virology, 2004, 78, 5591-5600.	3.4	131
21	Recruitment of activated IRF-3 and CBP/p300 to herpes simplex virus ICP0 nuclear foci: Potential role in blocking IFN-Î <sup>2</sup> induction. Virology, 2007, 360, 305-321.	2.4	126
22	Herpes Simplex Virus Immediate-Early ICPO Protein Inhibits Toll-Like Receptor 2-Dependent Inflammatory Responses and NF-κB Signaling. Journal of Virology, 2010, 84, 10802-10811.	3.4	118
23	Vaccine Protection against Simian Immunodeficiency Virus by Recombinant Strains of Herpes Simplex Virus. Journal of Virology, 2000, 74, 7745-7754.	3.4	109
24	Interferon Î <sup>3</sup> -inducible Protein (IFI) 16 Transcriptionally Regulates Type I Interferons and Other Interferon-stimulated Genes and Controls the Interferon Response to both DNA and RNA Viruses. Journal of Biological Chemistry, 2014, 289, 23568-23581.	3.4	106
25	Influence of Mucosal and Parenteral Immunization with a Replication-Defective Mutant of HSV-2 on Immune Responses and Protection from Genital Challenge. Virology, 1998, 243, 178-187.	2.4	104
26	Role of Specific Innate Immune Responses in Herpes Simplex Virus Infection of the Central Nervous System. Journal of Virology, 2012, 86, 2273-2281.	3.4	104
27	Role for herpes simplex virus 1 ICP27 in the inhibition of type I interferon signaling. Virology, 2008, 374, 487-494.	2.4	103
28	Cellular Sensing of Viral DNA and Viral Evasion Mechanisms. Annual Review of Microbiology, 2014, 68, 477-492.	7.3	103
29	Construction, Phenotypic Analysis, and Immunogenicity of a UL5/UL29 Double Deletion Mutant of Herpes Simplex Virus 2. Journal of Virology, 2000, 74, 7963-7971.	3.4	101
30	Comparative Efficacy and Immunogenicity of Replication-Defective, Recombinant Glycoprotein, and DNA Vaccines for Herpes Simplex Virus 2 Infections in Mice and Guinea Pigs. Journal of Virology, 2005, 79, 410-418.	3.4	101
31	Association of Herpes Simplex Virus Type 1 ICP8 and ICP27 Proteins with Cellular RNA Polymerase II Holoenzyme. Journal of Virology, 2002, 76, 5893-5904.	3.4	99
32	The Role of Tollâ€Like Receptors in Herpes Simplex Infection in Neonates. Journal of Infectious Diseases, 2005, 191, 746-748.	4.0	91
33	Herpesviral replication compartments move and coalesce at nuclear speckles to enhance export of viral late mRNA. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E136-44.	7.1	89
34	Accumulation of Viral Transcripts and DNA during Establishment of Latency by Herpes Simplex Virus. Journal of Virology, 1998, 72, 1177-1185.	3.4	85
35	Herpes simplex virus replication compartments can form by coalescence of smaller compartments. Virology, 2003, 309, 232-247.	2.4	81
36	Construction and Characterization of a Replication-Defective Herpes Simplex Virus 2 ICP8 Mutant Strain and Its Use in Immunization Studies in a Guinea Pig Model of Genital Disease. Virology, 1997, 232, 1-12.	2.4	79

#	Article	IF	CITATIONS
37	Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes. Science Translational Medicine, 2014, 6, 265ra169.	12.4	77
38	Nuclear sensing of viral DNA, epigenetic regulation of herpes simplex virus infection, and innate immunity. Virology, 2015, 479-480, 153-159.	2.4	76
39	Proteomics of herpes simplex virus infected cell protein 27: association with translation initiation factors. Virology, 2004, 330, 487-492.	2.4	71
40	Genetic analysis of the SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression and cell-to-cell fusion. Virology, 2005, 341, 215-230.	2.4	71
41	Genetic identification of a portion of the herpes simplex virus ICP8 protein required for DNA-binding. Virology, 1988, 163, 319-329.	2.4	69
42	Mechanisms of Immunization with a Replication-Defective Mutant of Herpes Simplex Virus 1. Virology, 1996, 220, 402-413.	2.4	69
43	Herpes Simplex Virus ICP27 Increases Translation of a Subset of Viral Late mRNAs. Journal of Virology, 2008, 82, 3538-3545.	3.4	69
44	Kinetics of Facultative Heterochromatin and Polycomb Group Protein Association with the Herpes Simplex Viral Genome during Establishment of Latent Infection. MBio, 2013, 4, .	4.1	69
45	Herpes Simplex Virus 1 ICP27 Is Required for Transcription of Two Viral Late (γ2) Genes in Infected Cells. Virology, 2001, 283, 273-284.	2.4	68
46	Herpes Simplex Virus 1 Immediate-Early and Early Gene Expression during Reactivation from Latency under Conditions That Prevent Infectious Virus Production. Journal of Virology, 2005, 79, 14516-14525.	3.4	68
47	Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2. Journal of Virology, 2015, 89, 8219-8232.	3.4	68
48	Assembly of Herpes Simplex Virus Replication Proteins at Two Distinct Intranuclear Sites. Virology, 1997, 229, 113-125.	2.4	66
49	Comparison of the Intranuclear Distributions of Herpes Simplex Virus Proteins Involved in Various Viral Functions. Virology, 1998, 252, 162-178.	2.4	66
50	Cutting Edge: Myeloid Complement C3 Enhances the Humoral Response To Peripheral Viral Infection. Journal of Immunology, 2001, 167, 2446-2451.	0.8	66
51	Persistent Elevated Expression of Cytokine Transcripts in Ganglia Latently Infected with Herpes Simplex Virus in the Absence of Ganglionic Replication or Reactivation. Virology, 2000, 278, 207-216.	2.4	65
52	Myeloid C3 Determines Induction of Humoral Responses to Peripheral Herpes Simplex Virus Infection. Journal of Immunology, 2003, 171, 5363-5371.	0.8	65
53	Role for A-Type Lamins in Herpesviral DNA Targeting and Heterochromatin Modulation. PLoS Pathogens, 2008, 4, e1000071.	4.7	65
54	Herpes Simplex Virus 1 Glycoprotein B and US3 Collaborate To Inhibit CD1d Antigen Presentation and NKT Cell Function. Journal of Virology, 2011, 85, 8093-8104.	3.4	65

#	Article	IF	CITATIONS
55	Herpes simplex virus-1 infection causes the secretion of a type I interferon-antagonizing protein and inhibits signaling at or before Jak-1 activation. Virology, 2010, 396, 21-29.	2.4	64
56	Herpes Simplex Virus Vectors Elicit Durable Immune Responses in the Presence of Preexisting Host Immunity. Journal of Virology, 2002, 76, 3678-3687.	3.4	62
57	Herpes simplex virus 1 microRNAs expressed abundantly during latent infection are not essential for latency in mouse trigeminal ganglia. Virology, 2011, 417, 239-247.	2.4	61
58	Herpesviral ICPO Protein Promotes Two Waves of Heterochromatin Removal on an Early Viral Promoter during Lytic Infection. MBio, 2016, 7, e02007-15.	4.1	61
59	Relative Contributions of Herpes Simplex Virus 1 ICPO and vhs to Loss of Cellular IFI16 Vary in Different Human Cell Types. Journal of Virology, 2016, 90, 8351-8359.	3.4	60
60	Neither LAT nor Open Reading Frame P Mutations Increase Expression of Spliced or Intron-Containing ICPO Transcripts in Mouse Ganglia Latently Infected with Herpes Simplex Virus. Journal of Virology, 2002, 76, 4764-4772.	3.4	59
61	Innate Immune Mechanisms and Herpes Simplex Virus Infection and Disease. Advances in Anatomy, Embryology and Cell Biology, 2017, 223, 49-75.	1.6	59
62	Latent Herpes Simplex Virus Infection of Sensory Neurons Alters Neuronal Gene Expression. Journal of Virology, 2003, 77, 9533-9541.	3.4	58
63	Contributions of Antibody and T Cell Subsets to Protection Elicited by Immunization with a Replication-Defective Mutant of Herpes Simplex Virus Type 1. Virology, 1997, 239, 315-326.	2.4	57
64	Protection from Herpes Simplex Virus (HSV)–2 Infection with Replicationâ€Defective HSVâ€2 or Glycoprotein D2 Vaccines in HSVâ€1–Seropositive and HSVâ€1–Seronegative Guinea Pigs. Journal of Infectious Diseases, 2009, 200, 1088-1095.	4.0	57
65	Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology, 2007, 357, 199-214.	2.4	54
66	A digenic human immunodeficiency characterized by IFNAR1 and IFNGR2 mutations. Journal of Clinical Investigation, 2017, 127, 4415-4420.	8.2	53
67	Macrophage-Derived Complement Component C4 Can Restore Humoral Immunity in C4-Deficient Mice. Journal of Immunology, 2002, 169, 5489-5495.	0.8	51
68	ATRX promotes maintenance of herpes simplex virus heterochromatin during chromatin stress. ELife, 2018, 7, .	6.0	51
69	Mechanisms of Host IFI16, PML, and Daxx Protein Restriction of Herpes Simplex Virus 1 Replication. Journal of Virology, 2018, 92, .	3.4	50
70	Herpes Simplex Virus Gene Products Required for Viral Inhibition of Expression of G1-Phase Functions. Virology, 2001, 290, 320-328.	2.4	49
71	Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation. Journal of Experimental Medicine, 2017, 214, 2315-2329.	8.5	49
72	Herpes simplex virus US3 tegument protein inhibits Toll-like receptor 2 signaling at or before TRAF6 ubiquitination. Virology, 2013, 439, 65-73.	2.4	48

#	Article	IF	CITATIONS
73	Evidence for Differences in Immunologic and Pathogenesis Properties of Herpes Simplex Virus 2 Strains From the United States and South Africa. Journal of Infectious Diseases, 2011, 203, 1434-1441.	4.0	43
74	Role for a Filamentous Nuclear Assembly of IF116, DNA, and Host Factors in Restriction of Herpesviral Infection. MBio, 2019, 10, .	4.1	43
75	Human Cytomegalovirus UL44 Concentrates at the Periphery of Replication Compartments, the Site of Viral DNA Synthesis. Journal of Virology, 2012, 86, 2089-2095.	3.4	42
76	Biological Properties of Herpes Simplex Virus 2 Replication-Defective Mutant Strains in a Murine Nasal Infection Model. Virology, 2000, 278, 137-150.	2.4	41
77	Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine, 2008, 26, 4034-4040.	3.8	41
78	Herpes Simplex Virus VP16, but Not ICP0, Is Required To Reduce Histone Occupancy and Enhance Histone Acetylation on Viral Genomes in U2OS Osteosarcoma Cells. Journal of Virology, 2010, 84, 1366-1375.	3.4	41
79	Role of Herpes Simplex Virus 1 γ34.5 in the Regulation of IRF3 Signaling. Journal of Virology, 2017, 91, .	3.4	40
80	Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity. Science Translational Medicine, 2019, 11, .	12.4	39
81	Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector. Virology, 2007, 357, 186-198.	2.4	38
82	Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins. Journal of Virology, 2015, 89, 8206-8218.	3.4	37
83	A Herpesviral Lytic Protein Regulates the Structure of Latent Viral Chromatin. MBio, 2016, 7, .	4.1	37
84	Identification of TRIM27 as a Novel Degradation Target of Herpes Simplex Virus 1 ICPO. Journal of Virology, 2015, 89, 220-229.	3.4	36
85	CNBP controls IL-12 gene transcription and Th1 immunity. Journal of Experimental Medicine, 2018, 215, 3136-3150.	8.5	36
86	CCCTC-Binding Factor Acts as a Heterochromatin Barrier on Herpes Simplex Viral Latent Chromatin and Contributes to Poised Latent Infection. MBio, 2018, 9, .	4.1	35
87	Regulation of host and virus genes by neuronal miR-138 favours herpes simplex virus 1 latency. Nature Microbiology, 2021, 6, 682-696.	13.3	35
88	The Role of Herpes Simplex Virus ICP27 in the Regulation of UL24 Gene Expression by Differential Polyadenylation. Journal of Virology, 1998, 72, 7709-7714.	3.4	35
89	Genetic engineering of a modified herpes simplex virus 1 vaccine vector. Vaccine, 2009, 27, 2760-2767.	3.8	31
90	Herpesviral lytic gene functions render the viral genome susceptible to novel editing by CRISPR/Cas9. ELife, 2019, 8	6.0	30

#	Article	IF	CITATIONS
91	Optimal Long-Term Humoral Responses to Replication-Defective Herpes Simplex Virus Require CD21/CD35 Complement Receptor Expression on Stromal Cells. Journal of Virology, 2006, 80, 7111-7117.	3.4	29
92	Roles of the Nuclear Lamina in Stable Nuclear Association and Assembly of a Herpesviral Transactivator Complex on Viral Immediate-Early Genes. MBio, 2012, 3, .	4.1	29
93	HIV Integrase Inhibitors Block Replication of Alpha-, Beta-, and Gammaherpesviruses. MBio, 2014, 5, e01318-14.	4.1	29
94	Genomic sequences of a low passage herpes simplex virus 2 clinical isolate and its plaque-purified derivative strain. Virology, 2014, 450-451, 140-145.	2.4	29
95	Inhibition of O-Linked <i>N</i> -Acetylglucosamine Transferase Reduces Replication of Herpes Simplex Virus and Human Cytomegalovirus. Journal of Virology, 2015, 89, 8474-8483.	3.4	29
96	Heparin octasaccharide decoy liposomes inhibit replication of multiple viruses. Antiviral Research, 2015, 116, 34-44.	4.1	29
97	ICP27 Selectively Regulates the Cytoplasmic Localization of a Subset of Viral Transcripts in Herpes Simplex Virus Type 1-Infected Cells. Journal of Virology, 2004, 78, 23-32.	3.4	28
98	Disruption of the UL41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology, 2008, 372, 165-175.	2.4	28
99	HSV-1 Remodels Host Telomeres to Facilitate Viral Replication. Cell Reports, 2014, 9, 2263-2278.	6.4	28
100	History and genomic sequence analysis of the herpes simplex virus 1 KOS and KOS1.1 sub-strains. Virology, 2016, 487, 215-221.	2.4	28
101	Identification of a Divalent Metal Cation Binding Site in Herpes Simplex Virus 1 (HSV-1) ICP8 Required for HSV Replication. Journal of Virology, 2012, 86, 6825-6834.	3.4	27
102	Simian TRIM5α proteins reduce replication of herpes simplex virus. Virology, 2010, 398, 243-250.	2.4	26
103	Herpes Simplex Virus 1 Lytic Infection Blocks MicroRNA (miRNA) Biogenesis at the Stage of Nuclear Export of Pre-miRNAs. MBio, 2019, 10, .	4.1	26
104	Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine, 2010, 28, 2754-2762.	3.8	25
105	Ensuring vaccine safety. Science, 2020, 370, 1274-1275.	12.6	24
106	CD200R1 Supports HSV-1 Viral Replication and Licenses Pro-Inflammatory Signaling Functions of TLR2. PLoS ONE, 2012, 7, e47740.	2.5	24
107	A Dominant Mutant Form of the Herpes Simplex Virus ICP8 Protein Decreases Viral Late Gene Transcription. Virology, 1996, 221, 281-290.	2.4	23
108	A Targeted RNA Interference Screen Reveals Novel Epigenetic Factors That Regulate Herpesviral Gene Expression. MBio, 2014, 5, e01086-13.	4.1	23

#	Article	IF	CITATIONS
109	Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector. Virology, 2016, 496, 186-193.	2.4	23
110	Evidence for a direct interaction between HSV-1 ICP27 and ICP8 proteins. Virology, 2005, 331, 94-105.	2.4	22
111	Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease. Virology, 2007, 368, 227-231.	2.4	22
112	Decreasing Herpes Simplex Viral Infectivity in Solution by Surface-Immobilized and Suspended N,N-Dodecyl,methyl-polyethylenimine. Pharmaceutical Research, 2013, 30, 25-31.	3.5	22
113	Summary and recommendations from a National Institute of Allergy and Infectious Diseases (NIAID) workshop on "Next Generation Herpes Simplex Virus Vaccines― Vaccine, 2014, 32, 1561-1562.	3.8	21
114	A virus-specific monocyte inflammatory phenotype is induced by SARS-CoV-2 at the immune–epithelial interface. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	21
115	A Dominant-Negative Herpesvirus Protein Inhibits Intranuclear Targeting of Viral Proteins: Effects on DNA Replication and Late Gene Expression. Journal of Virology, 2000, 74, 10122-10131.	3.4	20
116	Barrier-to-Autointegration Factor 1 (BAF/BANF1) Promotes Association of the SETD1A Histone Methyltransferase with Herpes Simplex Virus Immediate-Early Gene Promoters. MBio, 2015, 6, e00345-15.	4.1	19
117	Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia. Journal of Virology, 2019, 93, .	3.4	19
118	Model of vaccine efficacy against HSV-2 superinfection of HSV-1 seropositive mice demonstrates protection by antibodies mediating cellular cytotoxicity. Npj Vaccines, 2020, 5, 35.	6.0	19
119	ABIN-1 heterozygosity sensitizes to innate immune response in both RIPK1-dependent and RIPK1-independent manner. Cell Death and Differentiation, 2019, 26, 1077-1088.	11.2	18
120	Viral gene products actively promote latent infection by epigenetic silencing mechanisms. Current Opinion in Virology, 2017, 23, 68-74.	5.4	17
121	Proteomic analysis of the herpes simplex virus 1 virion protein 16 transactivator protein in infected cells. Proteomics, 2015, 15, 1957-1967.	2.2	16
122	C-terminal region of herpes simplex virus ICP8 protein needed for intranuclear localization. Virology, 2003, 309, 219-231.	2.4	15
123	Cellular SNF2H Chromatin-Remodeling Factor Promotes Herpes Simplex Virus 1 Immediate-Early Gene Expression and Replication. MBio, 2011, 2, e00330-10.	4.1	15
124	Tissue-Resident-Memory CD8+ T Cells Bridge Innate Immune Responses in Neighboring Epithelial Cells to Control Human Genital Herpes. Frontiers in Immunology, 2021, 12, 735643.	4.8	15
125	Combined cytotoxic activity of an infectious, but nonâ€replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells. Immunology, 2015, 146, 327-338.	4.4	14
126	Tripartite Motif 22 (TRIM22) protein restricts herpes simplex virus 1 by epigenetic silencing of viral immediate-early genes. PLoS Pathogens, 2021, 17, e1009281.	4.7	14

#	Article	IF	CITATIONS
127	Clues to mechanisms of herpesviral latent infection and potential cures. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11993-11994.	7.1	13
128	Intramuscular delivery of replication-defective herpes simplex virus gives antigen expression in muscle syncytia and improved protection against pathogenic HSV-2 strains. Virology, 2018, 513, 129-135.	2.4	13
129	Herpes Simplex Virus 1 Manipulates Host Cell Antiviral and Proviral DNA Damage Responses. MBio, 2021, 12, .	4.1	13
130	Classification of human Herpesviridae proteins using Domain-architecture Aware Inference of Orthologs (DAIO). Virology, 2019, 529, 29-42.	2.4	12
131	ATRX limits the accessibility of histone H3-occupied HSV genomes during lytic infection. PLoS Pathogens, 2021, 17, e1009567.	4.7	12
132	Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus. Virology, 2016, 488, 61-67.	2.4	11
133	Vaccination Route as a Determinant of Protective Antibody Responses against Herpes Simplex Virus. Vaccines, 2020, 8, 277.	4.4	11
134	Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH. Open Biology, 2020, 10, 190235.	3.6	11
135	Vesicular Stomatitis Virus Chimeras Expressing the Oropouche Virus Glycoproteins Elicit Protective Immune Responses in Mice. MBio, 2021, 12, e0046321.	4.1	9
136	Herpes simplex virus as a tool to define the role of complement in the immune response to peripheral infection. Vaccine, 2008, 26, 194-199.	3.8	8
137	Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA. Frontiers in Immunology, 2019, 10, 2.	4.8	8
138	The US3 Kinase of Herpes Simplex Virus Phosphorylates the RNA Sensor RIG-I To Suppress Innate Immunity. Journal of Virology, 2022, 96, JVI0151021.	3.4	8
139	Expression of SARS coronavirus 1 spike protein from a herpesviral vector induces innate immune signaling and neutralizing antibody responses. Virology, 2021, 559, 165-172.	2.4	7
140	Rethinking the Response to Emerging Microbes: Vaccines and Therapeutics in the Ebola Era—a Conference at Harvard Medical School. Journal of Virology, 2015, 89, 7446-7448.	3.4	6
141	The Use of Green Fluorescent Fusion Proteins to Monitor Herpes Simplex Virus Replication. Methods in Molecular Biology, 2009, 515, 239-248.	0.9	4
142	Screening Method for CRISPR/Cas9 Inhibition of a Human DNA Virus: Herpes Simplex Virus. Bio-protocol, 2020, 10, e3748.	0.4	3
143	A recombinant herpes virus expressing influenza hemagglutinin confers protection and induces antibody-dependent cellular cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2110714118.	7.1	2
144	CRISPR-Cas9 expressed in stably transduced cell lines promotes recombination and selects for herpes simplex virus recombinants. Current Research in Virological Science, 2022, 3, 100023.	3.5	2

#	Article	IF	CITATIONS
145	Replication-Defective Herpes Simplex Virus Mutant Strains as Genital Herpes Vaccines and Vaccine Vectors. , 2011, , 285-298.		1